<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01609907</url>
  </required_header>
  <id_info>
    <org_study_id>YH14700-101</org_study_id>
    <nct_id>NCT01609907</nct_id>
  </id_info>
  <brief_title>Pharmacokinetic Drug Interaction Between Rosuvastatin and Valsartan</brief_title>
  <official_title>A Randomized, Open-label, Multiple-dose, Crossover Study to Investigate the Pharmacokinetic Drug Interaction Between Rosuvastatin and Valsartan in Healthy Male Volunteer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yuhan Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yuhan Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to compare pharmacokinetics after single oral administration
      of rosuvastatin and valsartan each separately versus coadministration of rosuvastatin and
      valsartan in healthy male volunteers.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2011</start_date>
  <completion_date type="Actual">May 2012</completion_date>
  <primary_completion_date type="Actual">May 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax,ss of valsartan</measure>
    <time_frame>18 points up to Day 4</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUCt,ss of valsartan</measure>
    <time_frame>18 points up to Day 4</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax,ss of rosuvastatin</measure>
    <time_frame>18 points up to Day 4</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUCt,ss of rosuvastatin</measure>
    <time_frame>18 points up to Day 4</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>t1/2 of rosuvastatin</measure>
    <time_frame>18 points up to Day 4</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tmax,ss of valsartan</measure>
    <time_frame>18 points up to Day 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t1/2 of valsartan</measure>
    <time_frame>18 points up to Day 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmin,ss of valsartan</measure>
    <time_frame>18 points up to Day 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax,ss of rosuvastatin</measure>
    <time_frame>18 points up to Day 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmin,ss of rosuvastatin</measure>
    <time_frame>18 points up to Day 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t1/2 of rosuvastatin</measure>
    <time_frame>18 points up to Day 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax,ss of N-desmetyl rosuvastatin</measure>
    <time_frame>18 points up to Day 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUCt,ss of N-desmetyl rosuvastatin</measure>
    <time_frame>18 points up to Day 4</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Hypertension</condition>
  <condition>Hyperlipidemia</condition>
  <arm_group>
    <arm_group_label>Sequence 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence 6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rosuvastatin+Valsartan (Sequence 1)</intervention_name>
    <description>Period 1(A) Period 2(B) Period 3(C) A: Rosuvastatin 20mg (once daily for 4 consecutive days), B: Valsartan 160mg (once daily for 4 consecutive days), C: Rosuvastatin 20mg plus Valsartan 160mg (once daily for 4 consecutive days)</description>
    <arm_group_label>Sequence 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rosuvastatin+Valsartan (Sequence 2)</intervention_name>
    <description>Period 1(C) Period 2(A) Period 3(B) A: Rosuvastatin 20mg (once daily for 4 consecutive days), B: Valsartan 160mg (once daily for 4 consecutive days), C: Rosuvastatin 20mg plus Valsartan 160mg (once daily for 4 consecutive days)</description>
    <arm_group_label>Sequence 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rosuvastatin+Valsartan (Sequence 3)</intervention_name>
    <description>Period 1(B) Period 2(C) Period 3(A) A: Rosuvastatin 20mg (once daily for 4 consecutive days), B: Valsartan 160mg (once daily for 4 consecutive days), C: Rosuvastatin 20mg plus Valsartan 160mg (once daily for 4 consecutive days)</description>
    <arm_group_label>Sequence 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rosuvastatin+Valsartan (Sequence 4)</intervention_name>
    <description>Period 1(C) Period 2(B) Period 3(A) A: Rosuvastatin 20mg (once daily for 4 consecutive days), B: Valsartan 160mg (once daily for 4 consecutive days), C: Rosuvastatin 20mg plus Valsartan 160mg (once daily for 4 consecutive days)</description>
    <arm_group_label>Sequence 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rosuvastatin+Valsartan (Sequence 5)</intervention_name>
    <description>Period 1(B) Period 2(A) Period 3(C) A: Rosuvastatin 20mg (once daily for 4 consecutive days), B: Valsartan 160mg (once daily for 4 consecutive days), C: Rosuvastatin 20mg plus Valsartan 160mg (once daily for 4 consecutive days)</description>
    <arm_group_label>Sequence 5</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rosuvastatin+Valsartan (Sequence 6)</intervention_name>
    <description>Period 1(A) Period 2(C) Period 3(B) A: Rosuvastatin 20mg (once daily for 4 consecutive days), B: Valsartan 160mg (once daily for 4 consecutive days), C: Rosuvastatin 20mg plus Valsartan 160mg (once daily for 4 consecutive days)</description>
    <arm_group_label>Sequence 6</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male volunteers of aged between 20 years to 50 years

          -  Have a body mass index (BMI) between 19kg/m2 and 27kg/m2 inclusive

          -  Eligible subjects with acceptable medical history, physical examination laboratory
             tests, ECG during screening period

          -  Able to follow instruction and can participate in whole procedure of the trial

          -  Have signed a written informed consent voluntary, prior to the any procedure, using a
             form that is approved by the local Institutional Review Board after detail explanation
             of the drug

          -  Anticipate having the same adult female sexual partner, who have no possibility of
             being pregnant or breast-feeding and take steps to prevent conception during the study

        Exclusion Criteria:

          -  Have history of cardiovascular disorder(congestive heart failure, complications of
             coronary artery stenosis stroke and etc.), respiratory disorder, renal disorder(severe
             renal failure and etc.), liver disorder(moderate or severe liver failure and etc.)
             endocrine system disorder(diabetics, impaired glucose tolerance and etc.), digestive
             system disorder, central nervous system disorder, mental illness or malignant tumor

          -  Have history of gastrointestinal disease(Crohn's disease, ulcer and etc.),
             gastrointestinal surgery(simple appendectomy or herniotomy excluded) that can affect
             the absorption of the drug

          -  Have suffered from a clinically significant disease within 30 days prior to the first
             administration

          -  Have a known hypersensitivity or history of clinically significant hypersensitivity to
             drugs including the same class drugs with rosuvastatin or valsartan, or other
             drug(aspirin, antibiotics and etc.)

          -  Have genetic myopathy, family history of myopathy, or history of myopathy to drugs

          -  Have systolic blood pressure higher than 150mmHg or lower than 90mmHg, or diastolic
             blood pressure higher than 100mmHg or lower than 60mmHg, or pulse rate more than
             100times/min or less than 40times/min

          -  Have history of drug abuse or shown positive on drug abuse during drug screening test

          -  Participated in any other clinical trials within 90 days prior to the first
             administration

          -  Have used any herbal medicine, prescription drug, or generic medicine within 30 days,
             14 days or 7 days prior to the first administration, respectively (provided, however,
             if other conditions are judged to be eligible by investigators, subjects can
             participate in the trial)

          -  Donated whole blood or blood component within 60 days or 30 days prior to the first
             administration, respectively, or received transfusion within 30 days prior to the
             first administration

          -  Excessive alcohol drinker(&gt; 140g/week; 1 glass of 12° wine(125mL) = 12.0g, 1 glass of
             4° beer(250mL) = 8g, 0.5 bottle of soju(180mL) = 28.8g)

          -  Heavy smoker(&gt; 20 cigarettes/day)

          -  Excessive caffeine drinker(&gt; 4 cups/day)

          -  Shown positive on serum test(HBsAg, HCV Ab, HIV Ab tests)

          -  Subject who is judged to be ineligible by principal investigator or sub-investigator
             according to various reasons including their abnormal values in clinical laboratory
             test

          -  Continuous increase of liver enzyme level(AST, ALT) of unknown cause or active liver
             disorder patients with liver enzyme level increasing more than 3 time of normal upper
             limit

          -  Severe renal disorder patients(with creatinine clearance (Cr) &lt; 10mL/min when
             calculated with Modification of Diet in Renal Disease method)
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Woo-Seung Huh, MD, PhD.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Samsung Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Yuhan Corporation</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>January 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 5, 2012</study_first_submitted>
  <study_first_submitted_qc>May 31, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 1, 2012</study_first_posted>
  <last_update_submitted>May 31, 2012</last_update_submitted>
  <last_update_submitted_qc>May 31, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 1, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Drug interaction</keyword>
  <keyword>YH14700</keyword>
  <keyword>Rosuvastatin</keyword>
  <keyword>Valsartan</keyword>
  <keyword>Yuhan</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperlipidemias</mesh_term>
    <mesh_term>Hyperlipoproteinemias</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rosuvastatin Calcium</mesh_term>
    <mesh_term>Valsartan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

